文献速递临床试验与 GCP

重复阴道给予地诺前列酮(Propess®)促进足月孕妇引产是否有意义?(RE-DINO):一项随机对照试验的研究方案

Is there an interest in repeating the vaginal administration of dinoprostone (Propess®), to promote induction of labor of pregnant women at term? (RE-DINO): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2020-01-08

RE-DINO是一项在法国六家医院开展的前瞻性、开放标签、多中心、随机优效性试验,计划纳入360例≥18岁、>37周妊娠、首次放置Propess®后24小时宫颈条件不佳(Bishop评分<6)且胎头先露的孕妇。主要目的是比较第二次放置Propess®(必要时后续使用缩宫素)与直接注射缩宫素对阴道分娩率的影响,主要结局为阴道分娩率。

要点

  • 首次Propess®引产24小时后宫颈未成熟者,二次放置是否优于直接缩宫素尚不明确。
  • RE-DINO试验比较二次Propess®与直接缩宫素对阴道分娩率的影响。
  • 研究计划纳入360例足月单胎头位、Bishop评分<6的孕妇。

核心结论

  • 本研究旨在确定首次Propess®引产失败后,二次放置Propess®能否提高阴道分娩率。

研究设计与样本

  • 前瞻性、开放标签、多中心、随机优效性试验,两平行组,在六家法国医院开展。
  • 计划纳入360例≥18岁、>37周妊娠、首次Propess®放置24小时后Bishop评分<6、胎头先露的孕妇。
  • 排除早产胎膜早破、子宫瘢痕或多胎妊娠者。

关键数值与推荐

  • 主要结局为阴道分娩率。
  • 次要结局为引产失败率及母胎发病率与死亡率。
  • 干预组为第二次放置Propess®(必要时后续使用缩宫素),对照组为直接注射缩宫素。

临床怎么用

  • 研究结果可能为首次Propess®引产失败后的引产方式选择提供依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Labor is induced in over 20% of women in France. Prostaglandins, especially intravaginal dinoprostone (Propess®), are widely used to initiate cervical ripening. If labor does not start within 24 h, there is uncertainty about whether to administer a second dinoprostone pessary or to use oxytocin to induce labor in order to achieve a vaginal delivery. METHODS: RE-DINO is a prospective, open-label, multicenter, randomized superiority trial with two parallel arms running in six French hospitals. A total of 360 patients ≥ 18 years of age at > 37 weeks of gestation who exhibit unfavorable cervical conditions (Bishop score < 6) 24 h after placement of the first Propess®, with fetuses in cephalic presentation, will be included. Patients with premature membrane rupture, uterine scars, or multiple pregnancies will be excluded. Our principal objective is to determine whether placement of a second Propess® (followed by oxytocin [Syntocinon®], if necessary) in women for whom the first Propess® failed to induce cervical ripening increases the vaginal delivery rate compared to direct oxytocin injection. The vaginal delivery rate is therefore the primary outcome. The secondary outcomes are the induction failure rates and maternofetal morbidity and mortality. DISCUSSION: This study may help in determining the optimal way to induce labor after failure of a first Propess®, an unresolved problem to date. This trial explores the effectiveness and safety of placing a second Propess® and may contribute to development of an obstetric consensus. TRIAL REGISTRATION: Registered on 2 September 2016 at clinicaltrials.gov (identification number NCT02888041).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Coste Mazeau P, Hessas M, Martin R, et al. Is there an interest in repeating the vaginal administration of dinoprostone (Propess®), to promote induction of labor of pregnant women at term? (RE-DINO): study protocol for a randomized controlled trial. Trials. 2020. PMID: 31915047. doi:10.1186/s13063-019-3985-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。